{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:05:43Z","timestamp":1780448743275,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40618-020-01179-8","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T18:02:37Z","timestamp":1579024957000},"page":"959-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of renin\u2013angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"43","author":[{"given":"X.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,14]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047\u20131053","journal-title":"Diabetes Care"},{"key":"1179_CR2","unstructured":"IDF Diabetes Atlas, 9th edition 2019. https:\/\/diabetesatlas.org\/en\/resources\/. Retrieved 2 Dec 2019"},{"key":"1179_CR3","doi-asserted-by":"publisher","unstructured":"(2019) Introduction: standards of medical care in diabetes-2019. Diabetes Care 42:S1\u2013S2. https:\/\/doi.org\/10.2337\/dc19-Sint01","DOI":"10.2337\/dc19-Sint01"},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.dsx.2018.11.054","volume":"13","author":"VR Albvr","year":"2019","unstructured":"Albvr VR, Tan SH, Candasamy M, Bhattamisra SK (2019) Diabetic nephropathy: an update on pathogenesis and drug development. Diabetes Metab Syndr 13:754\u2013762","journal-title":"Diabetes Metab Syndr"},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2337\/diacare.28.1.164","volume":"28","author":"JL Gross","year":"2005","unstructured":"Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML et al (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164\u2013176","journal-title":"Diabetes Care"},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","volume":"54","author":"AS Levey","year":"2009","unstructured":"Levey AS, Cattran D, Friedman A, Miller WG, Sedor J et al (2009) Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 54:205\u2013226","journal-title":"Am J Kidney Dis"},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MBP.0b013e32833a23d4","volume":"15","author":"Y Lv","year":"2010","unstructured":"Lv Y, Zou Z, Chen GM, Jia HX, Zhong J et al (2010) Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit 15:195\u2013204","journal-title":"Blood Press Monit"},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/jch.12388","volume":"16","author":"L Wu","year":"2014","unstructured":"Wu L, Deng SB, She Q (2014) Calcium channel blocker compared with angiotensin receptor blocker for patients with hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich) 16:838\u2013845","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"1179_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"1179_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/0272989X05282643","volume":"25","author":"AE Ades","year":"2005","unstructured":"Ades AE, Lu G, Higgins JP (2005) The interpretation of random-effects meta-analysis in decision models. Med Decis Making 25:646\u2013654","journal-title":"Med Decis Making"},{"key":"1179_CR13","first-page":"501","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JJ Deeks","year":"2008","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2008) Analyzing data and undertaking meta-analyses. In: Higgins JP, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, Oxford, p 501"},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"1179_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326:219","journal-title":"BMJ"},{"key":"1179_CR16","first-page":"15","volume":"47","author":"A Tobias","year":"1999","unstructured":"Tobias A (1999) Assessing the influence of a single study in meta-analysis. Stata Tech Bull 47:15\u201317","journal-title":"Stata Tech Bull"},{"key":"1179_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"1179_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"1179_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/bmj.299.6698.533","volume":"299","author":"HH Parving","year":"1989","unstructured":"Parving HH, Hommel E, Damkjaer Nielsen M, Giese J (1989) Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 299:533\u2013536","journal-title":"BMJ"},{"key":"1179_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0272-6386(12)70256-1","volume":"20","author":"JH Bauer","year":"1992","unstructured":"Bauer JH, Reams GP, Hewett J, Klachko D, Lau A et al (1992) A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 20:443\u2013457","journal-title":"Am J Kidney Dis"},{"key":"1179_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","volume":"118","author":"M Ravid","year":"1993","unstructured":"Ravid M, Savin H, Jutrin I, Bental T, Katz B et al (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577\u2013581","journal-title":"Ann Intern Med"},{"key":"1179_CR22","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456\u20131462","journal-title":"N Engl J Med"},{"key":"1179_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0002-9343(99)80226-5","volume":"99","author":"LM Laffel","year":"1995","unstructured":"Laffel LM, McGill JB, Gans DJ (1995) The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 99:497\u2013504","journal-title":"Am J Med"},{"key":"1179_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, Locatelli F, Mann JF et al (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939\u2013945","journal-title":"N Engl J Med"},{"key":"1179_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/(SICI)1096-9136(199602)13:2<120::AID-DIA6>3.0.CO;2-F","volume":"13","author":"T Sano","year":"1996","unstructured":"Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S et al (1996) Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabet Med 13:120\u2013124","journal-title":"Diabet Med"},{"key":"1179_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0026-0495(98)90364-X","volume":"47","author":"A Nankervis","year":"1998","unstructured":"Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S et al (1998) Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 47:12\u201315","journal-title":"Metabolism"},{"key":"1179_CR27","doi-asserted-by":"crossref","unstructured":"(2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet 355:253\u2013259","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"1179_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0168-8227(01)00289-3","volume":"55","author":"S Katayama","year":"2002","unstructured":"Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N et al (2002) Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 55:113\u2013121","journal-title":"Diabetes Res Clin Pract"},{"key":"1179_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","volume":"328","author":"M Marre","year":"2004","unstructured":"Marre M, Lievre M, Chatellier G, Mann JF, Passa P et al (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495","journal-title":"BMJ"},{"key":"1179_CR30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, Grop AC, MacMahon S, Chalmers J, Neal B et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829\u2013840","journal-title":"Lancet"},{"key":"1179_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A et al (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40\u201351","journal-title":"N Engl J Med"},{"key":"1179_CR32","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892\u20131903","journal-title":"N Engl J Med"},{"key":"1179_CR33","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870\u2013878","journal-title":"N Engl J Med"},{"key":"1179_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"1179_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"1179_CR36","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S et al (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225\u20131237","journal-title":"N Engl J Med"},{"key":"1179_CR37","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","volume":"372","author":"N Chaturvedi","year":"2008","unstructured":"Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J et al (2008) Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372:1394\u20131402","journal-title":"Lancet"},{"issue":"11\u201320","key":"1179_CR38","first-page":"W13","volume":"151","author":"R Bilous","year":"2009","unstructured":"Bilous R, Chaturvedi N, Sjolie AK, Fuller J, Klein R et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151(11\u201320):W13\u201314","journal-title":"Ann Intern Med"},{"key":"1179_CR39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","volume":"372","author":"AK Sjolie","year":"2008","unstructured":"Sjolie AK, Klein R, Porta M, Orchard T, Fuller J et al (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372:1385\u20131393","journal-title":"Lancet"},{"key":"1179_CR40","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F et al (2011) Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54:2978\u20132986","journal-title":"Diabetologia"},{"key":"1179_CR41","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907\u2013917","journal-title":"N Engl J Med"},{"key":"1179_CR42","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.amjcard.2013.07.043","volume":"112","author":"K Yamashita","year":"2013","unstructured":"Yamashita K, Kondo T, Muramatsu T, Matsushita K, Nagahiro T et al (2013) Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. Am J Cardiol 112:1750\u20131756","journal-title":"Am J Cardiol"},{"key":"1179_CR43","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/ajh.2008.206","volume":"21","author":"PA Sarafidis","year":"2008","unstructured":"Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN (2008) Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens 21:922\u2013929","journal-title":"Am J Hypertens"},{"key":"1179_CR44","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/heartjnl-2014-307119","volume":"101","author":"ZJ Wang","year":"2015","unstructured":"Wang ZJ, Zhou YJ, Galper BZ, Gao F, Yeh RW et al (2015) Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart 101:1631\u20131638","journal-title":"Heart"},{"key":"1179_CR45","doi-asserted-by":"publisher","first-page":"e0170955","DOI":"10.1371\/journal.pone.0170955","volume":"12","author":"W Qi","year":"2017","unstructured":"Qi W, Zhang N, Korantzopoulos P, Letsas KP, Cheng M et al (2017) Serum glycated hemoglobin level as a predictor of atrial fibrillation: A systematic review with meta-analysis and meta-regression. PLoS ONE 12:e0170955","journal-title":"PLoS ONE"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01179-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-020-01179-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01179-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T21:59:25Z","timestamp":1610575165000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-020-01179-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,14]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01179-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,14]]},"assertion":[{"value":"31 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}